Core Viewpoint - Chengyi Pharmaceutical (603811.SH) reported a significant increase in both revenue and net profit for the first half of the year, indicating strong operational performance and effective management strategies [1] Financial Performance - The company achieved operating revenue of 416.67 million yuan, representing a year-on-year growth of 17.11% [1] - The net profit attributable to shareholders reached 112.42 million yuan, reflecting a year-on-year increase of 47.03% [1] Quality Management and Production - The company conducted a special audit of raw material suppliers to enhance on-site management and ensure product quality from the source [1] - Continuous GMP training and comprehensive implementation of quality risk management were emphasized, utilizing supplier audits, deviation change management, and process monitoring to strengthen GMP management [1] - Production operations were arranged according to market demands, ensuring safe, environmentally friendly, and high-quality completion of production tasks, with the company recognized as a green factory in Wenzhou for 2024 [1]